CHCWM – Cancer & Hematology Centers of West Michigan

LYT-200-2020-01 (PureTech Health LLC)

Description:  A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in

Patients with Metastatic Solid Tumors

Mechanism of Action:  monoclonal antibody targeting galectin-9 (a novel immunotherapy target)

Target Patient Population:   All solid tumors. 

Study Design:  Drug is given IV every 2 weeks of a 28 day cycle